Glycaemic and lipid effects of pioglitazone and rosiglitazone in patients naive to oral antidiabetic medications

被引：0
|
作者：
Shinall, S.
Buse, J.
Tan, M.
Gbenado, S.
Spanheimer, R.
机构：
[1] Takeda Pharmaceut N Amer Inc, Lincoln, NE USA
[2] Univ N Carolina, Sch Med, Div Gen Internal Med & Clin Epidemiol, Chapel Hill, NC USA
[3] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[4] Takeda Global Res & Dev Ctr, Biometr & Data Management, Lincoln, NE USA
来源：
DIABETOLOGIA | 2006年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1160
引用
收藏
页码：703 / 704
页数：2
相关论文
共 50 条
  • [1] A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
    Goldberg, RB
    Kendall, DM
    Deeg, MA
    Buse, JB
    Zagar, AJ
    Pinaire, JA
    Tan, MH
    Khan, MA
    Perez, AT
    Jacober, SJ
    [J]. DIABETES CARE, 2005, 28 (07) : 1547 - 1554
  • [2] Pioglitazone:: update on an oral antidiabetic drug with antiatherosclerotic effects
    Pfuetzner, Andreas
    Weber, Matthias M.
    Forst, Thomas
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (12) : 1985 - 1998
  • [3] A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
    Goldberg, RB
    Kendall, DM
    Deeg, MA
    Buse, JB
    Zagar, AJ
    Pinaire, JA
    Tan, MH
    Khan, MA
    Perez, AT
    Jacober, SJ
    [J]. CIRCULATION, 2005, 111 (13) : 1727 - 1728
  • [4] Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone
    LaCivita, KA
    Villarreal, G
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (06) : 363 - 370
  • [5] Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes
    Dorkhan, M.
    Magnusson, M.
    Frid, A.
    Grubb, A.
    Groop, L.
    Jovinge, S.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2006, 260 (02) : 125 - 133
  • [6] The Impact of Adherence to Antidiabetic Medications on Glycaemic Control in Type 2 Diabetes Patients
    Wright, Alison K.
    Ashcroft, Darren M.
    Rutter, Martin K.
    Emsley, Richard
    Steinke, Douglas T.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 505 - 505
  • [7] Hypoglycaemia with Oral Antidiabetic DrugsResults from Prescription-Event Monitoring Cohorts of Rosiglitazone, Pioglitazone, Nateglinide and Repaglinide
    Veronika Vlckova
    Victoria Cornelius
    Rachna Kasliwal
    Lynda Wilton
    Saad A. W. Shakir
    [J]. Drug Safety, 2009, 32 : 409 - 418
  • [8] Different effects of pioglitazone and rosiglitazone on lipid metabolism in mouse cultured liver explants
    Djaouti, Louiza
    Jourdan, Tony
    Demizieux, Laurent
    Chevrot, Michael
    Gresti, Joseph
    Verges, Bruno
    Degrace, Pascal
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2010, 26 (04) : 297 - 305
  • [9] Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: A cross-sectional, observational pilot study
    Gul, Ozen Oz
    Cinkilic, Nilufer
    Gul, Cuma Bulent
    Cander, Soner
    Vatan, Ozgur
    Ersoy, Canan
    Yilmaz, Dilek
    Tuncel, Ercan
    [J]. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2013, 757 (01) : 31 - 35
  • [10] Clinical impact of oral antidiabetic medications in heart failure patients
    Alberto Palazzuoli
    Elena Ceccarelli
    Gaetano Ruocco
    Ranuccio Nuti
    [J]. Heart Failure Reviews, 2018, 23 : 325 - 335
12345